On March 13, 2018 – Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ: CKPT), a
clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development
and commercialization of novel treatments for patients with solid tumor cancers, reported that
James F. Oliviero, President and Chief Executive Officer, will participate in two investor conferences in
March (Press release, Checkpoint Therapeutics, MAR 13, 2018, View Source [SID1234525086]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
• Oppenheimer’s 28th Annual Healthcare Conference: Checkpoint will host one-on-one meetings
on Wednesday, March 21, 2018, at the Westin New York Grand Central in New York City
• The Wall Street Investor Forum 26th Annual Growth Conference: Checkpoint will present a
company overview on Thursday, March 22, 2018, at 11:50 a.m. EDT at The University Club of New
York in New York City
A live webcast of The Wall Street Investor Forum presentation will be available on the Events page of the
Investors & Media section of Checkpoint’s website: www.checkpointtx.com. An archived replay of the
webcast will be available for approximately 30 days following the presentation.